Seeking more options for celiac disease? Consider the ILLUMINATE-062 Study, which is evaluating an investigational drug designed to break down gluten in the stomach and improve control of celiac disease for people on a gluten-free diet.

UVA Tracking #
HSR230208
Principal Investigator
Dennis Kumral
Contact
Lakin Underwood
Contact Email
Contact Phone
434.924.0818
Official Trial Title
A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet
Study Description

The GI Research Department seeks adults ages 18+ with biopsy-confirmed celiac disease to evaluate an investigational drug designed to break down gluten in the stomach and improve control of celiac disease for people on a gluten-free diet.

If you occasionally experience celiac-related gastrointestinal symptoms, despite trying to follow a gluten-free diet, this study may be a good fit for you. Participants must have been on a gluten-free diet for at least the past 12 months.

The study will evaluate how well the investigational medication reduces celiac-related symptoms and intestinal damage due to gluten exposure. The study medication (investigational or placebo) is an oral pill that should be taken 3 times per day within 15 minutes of the start of a meal. The study has about 7 clinical visits, to include and total study duration per participant is up to 36 weeks. Participant electronic diaries, 2 upper GI endoscopies, 3 Video Capsule Endoscopies and bloodwork are required.

All study-related care is provided at no cost, compensation for your time and travel may be available, and some visits can be performed at home.

Compensation

$2,866